New eye drug regimen could mean fewer shots for PCV patients
NCT ID NCT07389980
First seen Feb 05, 2026 · Last updated Jun 23, 2026 · Updated 17 times
Summary
This phase 3 trial is testing a personalized treatment plan using high-dose aflibercept (8 mg) for people with polypoidal choroidal vasculopathy (PCV), a condition that causes vision loss. The goal is to see if adjusting the injection schedule based on each person's response can extend the time between treatments to 8–24 weeks. The study will enroll 50 adults with active PCV and follow them for 96 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYPOIDAL CHOROIDAL VASCULOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yeungnam University Hospital
RECRUITINGDaegu, 42415, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aflibercept 8 mg (a drug injected into the eye to block abnormal blood vessel growth)
What this could lead to
If successful, this could allow people with PCV to go longer between eye injections—up to 6 months—while still controlling the disease.
What could go wrong
This is a small, early-phase trial with only 50 participants. The personalized dosing schedule may not work for everyone, and there are risks like eye infection or inflammation from the injections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.